- Home
- FORM vs RYTM Comparison
FORM vs RYTM Comparison
Compare FORM & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORM
- RYTM
- Stock Information
- Founded
- FORM 1993
- RYTM 2008
- Country
- FORM United States
- RYTM United States
- Employees
- FORM N/A
- RYTM N/A
- Industry
- FORM Semiconductors
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FORM Technology
- RYTM Health Care
- Exchange
- FORM Nasdaq
- RYTM Nasdaq
- Market Cap
- FORM 2.9B
- RYTM 3.2B
- IPO Year
- FORM N/A
- RYTM 2017
- Fundamental
- Price
- FORM $28.29
- RYTM $52.97
- Analyst Decision
- FORM Buy
- RYTM Strong Buy
- Analyst Count
- FORM 8
- RYTM 12
- Target Price
- FORM $48.00
- RYTM $68.58
- AVG Volume (30 Days)
- FORM 794.6K
- RYTM 521.7K
- Earning Date
- FORM 04-30-2025
- RYTM 05-06-2025
- Dividend Yield
- FORM N/A
- RYTM N/A
- EPS Growth
- FORM N/A
- RYTM N/A
- EPS
- FORM 0.89
- RYTM N/A
- Revenue
- FORM $763,599,000.00
- RYTM $130,126,000.00
- Revenue This Year
- FORM $4.29
- RYTM $45.46
- Revenue Next Year
- FORM $7.08
- RYTM $63.04
- P/E Ratio
- FORM $32.01
- RYTM N/A
- Revenue Growth
- FORM 15.16
- RYTM 68.06
- 52 Week Low
- FORM $27.55
- RYTM $35.17
- 52 Week High
- FORM $63.63
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- FORM 30.00
- RYTM 48.25
- Support Level
- FORM $30.75
- RYTM $52.54
- Resistance Level
- FORM $32.65
- RYTM $55.21
- Average True Range (ATR)
- FORM 1.09
- RYTM 2.09
- MACD
- FORM -0.12
- RYTM 0.37
- Stochastic Oscillator
- FORM 13.19
- RYTM 49.48
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc designs, develops, manufactures, sells, and supports semiconductor probe card products. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.